CHARLOTTE, N.C., April 5, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 10th Annual Needham Healthcare Conference at 2:00 PM ET on Wednesday April 6, 2011 at the New York Palace Hotel in New York City.
Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide...
CHARLOTTE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference at 9:00 AM PT on March 15, 2011 at The Ritz-Carlton, Laguna Niguel.
Nick Riehle, Chelsea's Chief Financial Officer, will provide a brief overview of the company's p...
CHARLOTTE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2010 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide an update on the Company's development progress.2010 Highlights
Me...
CHARLOTTE, N.C., Feb. 25, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year 2010 results after the market closes on Wednesday, March 2, 2011. Chelsea management will host a conference call and live webcast to discuss these financial results and provide an upda...
CHARLOTTE, N.C., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced public offering of common stock and announced that the underwriters exercised their option to purchase approximately 1.3 million additional shares to cover over-allotments. Exercise of the full over-allotm...
CHARLOTTE, N.C., Feb. 18, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced a public offering of 8.75 million shares of its common stock at a price of $4.00 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and comm...
CHARLOTTE, N.C., Feb. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention, subject to market and other conditions, to offer $35 million in shares of its common stock in a registered public offering pursuant to its existing shelf registration statement. The company also intends to grant t...
CHARLOTTE, N.C., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual BIO CEO & Investor Conference at 1:30 PM ET on Monday, February 14th at the Waldorf Astoria Hotel in New York City.
In addition to a brief overview of the company's product pipeline, clinical devel...
Independent Data Monitoring Committee Concludes Continuation of Study Using Subjective OHQ Composite Endpoint Futile While Unblinded Analysis Reveals Robust Efficacy Reflected in Objective Falls EndpointParkinson's Disease Patients Treated With Northera Demonstrate 60% Decrease in Falls Chelsea Plans to File Primary Northera NDA for Symptomatic Neu...
Patients Continue to Report Statistically Significant 2.8 Unit Improvement in OHQ Composite Scores Following 12 Months of Open Label Treatment With Northera (p...
Chelsea to File for US Marketing Approval of Northera in Symptomatic Neurogenic Orthostatic Hypotension in Q2 2011 Based on Efficacy Data from Phase III Studies 301 and 302 FDA Will Not Require Study 306 as Second Pivotal Study for NDAManagement to Host Conference Call at 9:00 AM ET
CHARLOTTE, N.C., Dec. 20, 2010 (GLOBE NEWSWIRE) -- Chelsea Th...
CHARLOTTE, N.C., Dec. 14, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will webcast its session at the 2010 Deutsche Bank BioFEST at 11:30 a.m. ET on Tuesday, December 14, 2010.
Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide a brief overview of the company's product pipeline, c...
CHARLOTTE, N.C., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2010 and presented a quarterly update on the Company's development progress. Chelsea's management team will host a conference call this afternoon at 4:30 PM EDT to discuss these results.Recent Hi...
CHARLOTTE, N.C., Oct. 29, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Oppenheimer 21st Annual Healthcare Conference at 1:35 PM on Tuesday, November 2, 2010 at the Waldorf Astoria Hotel in New York.
Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a brief ...
CHARLOTTE, N.C., Oct. 27, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended Sept 30, 2010 after the market closes on Monday, November 1, 2010. Chelsea management will host a conference call and live webcast to discuss these financial results and...
CHARLOTTE, N.C., Oct. 19, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 2010 Newsmakers in the Biotechnology Industry Conference at 3:00 PM ET on Friday October 22, 2010 at the Millennium Hotel in New York City.
Keith Schmidt, Chelsea's vice president of sales and marketing, will p...
CHARLOTTE, N.C., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced public offering of common stock and announced that the underwriters exercised their option to purchase approximately 1.07 million additional shares to cover over-allotments. Exercise of the full over-allot...
CHARLOTTE, N.C., Oct. 1, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting disc...
CHARLOTTE, N.C., Sept. 28, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention, subject to market and other conditions, to offer $35 million in shares of its common stock in a registered public offering pursuant to its existing shelf registration statement. The company also intends to grant...
CHARLOTTE, N.C., Sept. 27, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate resp...
Delicious
Digg
Facebook
LinkedIn
Twitter
